Astellas Pharma (OTCMKTS:ALPMY) Shares Gap Down – Should You Sell?

Astellas Pharma Inc. (OTCMKTS:ALPMY)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $16.48, but opened at $15.87. Astellas Pharma shares last traded at $16.28, with a volume of 25,124 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ALPMY. Jefferies Financial Group raised shares of Astellas Pharma from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 24th. Smbc Nikko Sec. raised shares of Astellas Pharma to a “hold” rating in a research note on Monday, February 16th. Finally, Citigroup downgraded shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold”.

Astellas Pharma Stock Performance

The firm has a 50-day moving average price of $15.55 and a 200 day moving average price of $13.44. The firm has a market capitalization of $29.35 billion, a PE ratio of 13.63 and a beta of 0.17. The company has a quick ratio of 0.84, a current ratio of 1.09 and a debt-to-equity ratio of 0.23.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, February 4th. The company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.29 by $0.15. Astellas Pharma had a return on equity of 23.62% and a net margin of 15.63%.The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.21 billion. Research analysts expect that Astellas Pharma Inc. will post 0.42 earnings per share for the current year.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).